Objectives To assess efficacy of adjuvant (postoperative) chemotherapy for endometrial cancer. This systematic review examines the effect of chemotherapy on survival after hysterectomy for endometrial cancer. Adjuvant (postoperative) chemotherapy improves survival from some other adenocarcinomas, and there is evidence that endometrial cancer is sensitive to cytotoxic therapy. Survival depends the risk of microscopic metastases after surgery. It is distinct from sarcomas (tumours of the uterine muscle). Johnson, Nick Bryant, Andrew Miles, Tracie Hogberg, Thomas Cornes, Paulīackground Endometrial adenocarcinoma (womb cancer) is a malignant growth of the lining (endometrium) of the womb (uterus). PMID:26677436Īdjuvant chemotherapy for endometrial cancer after hysterectomy The present review discusses the strengths and weaknesses of the current evidence-base and suggests improvements for future studies. It has become evident that not all the patients respond to adjuvant chemotherapy and more personalised approach should be employed when considering the benefits of adjuvant chemotherapy.
However, concerns exist regarding the quality of the studies including inadequate staging modalities, out-dated chemotherapeutic regimens and surgical approaches and small sample sizes.
Results of recent multicentre randomised control trials showed no benefit of adjuvant chemotherapy in terms of survival and rates of distant metastases. However, controversy surrounds the use adjuvant chemotherapy in patients who received preoperative chemoradiotherapy, despite it being recommended by a number of international guidelines. The benefits of adjuvant chemotherapy after surgery alone have been well established. Milinis, Kristijonas Thornton, Michael Montazeri, Amir Rooney, Paul SĪdjuvant chemotherapy has become a standard treatment of advanced rectal cancer in the West. Adjuvant chemotherapy for rectal cancer: Is it needed?